A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II)

Inclusion Criteria: * Diagnosis of AML (de novo, secondary or with an antecedent hematologic disorder \[AHD\]) * Age ≥ 60 years * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Presence of at least one adverse prognostic factor: Age ≥ 70 years; or AHD; or ECOG performance status of 2; or Intermediate or unfavorable (i.e., adverse) karyotype defined as any cytogenetic profile except the presence of any of the following: * t(8;21)(q22;q22) * inv(16)(p13;q22 or t(16;16)(p13;q22) * t(15;17)(q22;q12) and variants. * Adequate renal and hepatic function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN; and Serum creatinine ≤ 1.0 mg/dL; if serum creatinine \> 1.0 mg/dL, then the estimated glomerular filtration rate (GFR) must be \> 60 mL/min/1.73 m\^2 as calculated by the Modification of Diet in Renal Disease (MDRD) equation * Adequate cardiac function: left ventricular ejection fraction (LVEF) ≥ 40% or left ventricular fractional shortening ≥ 22% Exclusion Criteria: * Diagnosis of acute promyelocytic leukemia * Prior treatment with clofarabine * Prior treatment for AML or an antecedent hematologic disorder * Prior hematopoietic stem cell transplant (HSCT) * Prior radiation therapy to the pelvis * Investigational agent received within 30 days prior to the first dose of study drug * Ongoing uncontrolled systemic infection * Diagnosis of another malignancy, unless the patient has been disease-free for at least 5 years following the completion of curative intent therapy with the following exceptions: Patients with treated non-melanoma skin cancer, in-situ carcinoma or cervical intraepithelial neoplasia regardless of disease-free duration are eligible for this study if definitive treatment for the condition has been completed; Patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease based on PSA value are eligible for this study if hormonal therapy has been initiated or a radical prostatectomy has been performed * Clinical evidence of central nervous system (CNS) involvement * Severe concurrent medical condition or psychiatric disorder that would preclude study participation * Positive human immunodeficiency virus (HIV) test